ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment to: Hashiya N, Maruko I, Maruko R et al. Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2026) 264:1611-1617. doi:10.1007/s00417-026-07117-3.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to compare intraocular pressure (IOP) changes before and after intravitreal injection of aflibercept 8 mg and 2 mg for neovascular age-related macular degeneration (nAMD).
methodsForty-one eyes of 41 patients were included. Twenty eyes received aflibercept 8 mg (8 mg group), and 21 eyes received aflibercept 2 mg (2 mg group). IOP was measured at baseline (T0), immediately before injection (T1), immediately after injection (T2), and 30 min post-injection (T3). T1 and T2 were measured using the iCare IC200 (Icare Oy, Finland) in the supine position, while T0 and T3 in the 8 mg group were assessed using the TONOREF II (NIDEK, Japan) in the sitting position.
resultsIn the 8 mg group, the mean IOP increased from 20.8 ± 4.0 mmHg at T1 to 67.2 ± 9.4 mmHg at T2. In the 2 mg group, IOP rose from 18.7 ± 4.0 mmHg to 55.7 ± 11.8 mmHg (P < 0.01 for both). The IOP increase was significantly greater in the 8 mg group (P < 0.01). At T3, the mean IOP in the 8 mg group decreased to 18.1 ± 5.9 mmHg but remained higher than T0 (13.2 ± 2.6 mmHg, P < 0.01). One glaucoma patient required medication due to sustained IOP elevation (38 mmHg) at T3, and another required anterior chamber paracentesis for IOP of 83 mmHg at T2.
conclusionsAflibercept 8 mg significantly increases IOP immediately after injection compared to 2 mg, though IOP generally normalizes within 30 min. Careful monitoring is advised, especially in glaucoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.